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Summary 
Background: Ivermectin has been identified as a potential new vector control tool to reduce malaria 
transmission. Mosquitoes feeding on a bloodmeal containing ivermectin have been shown to have a 
reduced lifespan, meaning they are less likely to live long enough to complete sporogony and become 
infectious.  
Methods: In this study, we validate an existing population-level mathematical model of the impact of 
ivermectin on the mosquito population and malaria transmission to entomological and clinical data. 
The model is extended to include a range of complementary malaria interventions and to incorporate 
new data on higher doses with a longer mosquitocidal effect. We then simulate the impact of these 
doses in a range of usage scenarios in different transmission settings.  
Findings: Mass drug administration (MDA) with ivermectin is predicted to reduce prevalence and 
incidence and is most effective in areas with a relatively short transmission season. In a highly seasonal 
moderate transmission setting, three rounds of ivermectin-only MDA spaced one month apart with a 
dose of 3x300µg/kg and 70% coverage is predicted to reduce clinical incidence by 71% and prevalence 
by 34% We predict that adding ivermectin MDA to seasonal malaria chemoprevention in this setting 
will reduce clinical incidence by an additional 77% in under 5-year olds. Adding ivermectin MDA to 
MDA with antimalarials in this setting is predicted to reduce incidence by an additional 75%.  
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Interpretation: Ivermectin is a novel vector control tool that targets residual transmission, it has an 
excellent safety profile and has operationally synergistic distribution schedules with existing malaria 
interventions. Based on modelling predictions in this study, we propose that this drug could be a 
valuable addition to the malaria control toolbox, both in areas with persistently high transmission 
where existing vector control is insufficient and in areas approaching elimination to prevent 
resurgence.  
Funding: Imperial College Junior Research Fellowship 
Research in context 
Evidence before this study 
We searched PubMed and ScienceDirect on August 17th, 2019, for studies using mathematical models 
to assess the impact of ivermectin (to humans) on malaria prevalence and incidence, using the search 
terms “ivermectin” AND “malaria” AND (“modelling” OR “modeling”). The search was unrestricted by 
language or publication date. Using this search and by scanning reference lists of articles, we identified 
three publications in peer-reviewed journals. Slater et al.  found that adding a single dose of ivermectin 
200 μg/kg would only have a modest effect on reduction of malaria prevalence if distributed in mass 
drug administration (MDA) with dihydroartemisinin-piperaquine (DHA-P), although higher doses of 
ivermectin were predicted to have a greater and longer-lasting effect. However, a model developed 
by Stuckey and colleagues predicted that adding ivermectin to MDA with DHA-P in Zambia would have 
a negligible additional effect. Finally a theoretical mathematical model by Ngwa et al. predicts that 
treating symptomatic individuals with ivermectin would reduce the reproduction number of malaria. 
Added value of this study 
We present the first population-level mathematical model of the impact of ivermectin on the 
mosquito population and malaria transmission that has been validated to clinical and entomological 
field data. Furthermore, the model incorporates new empirical data on higher doses with a longer 
mosquitocidal effect and has been extended to assess ivermectin alone and in combination with a 
range of complementary malaria interventions, including mass drug administration and seasonal 
malaria chemoprevention. By simulating impact in a range of usage scenarios in different transmission 
settings, our study shows that mass drug administration with ivermectin is predicted to reduce 
prevalence and incidence and is most effective in areas with a relatively short transmission season. 
When used in combination with seasonal malaria chemoprevention or mass drug administration with 
antimalarials, we predict that ivermectin will increase and prolong the impact of these interventions. 
Implications of all the available evidence 
Our modelling results indicate that ivermectin alone, and to a greater extent when combined with 
antimalarial drugs, is predicted to have a major and prolonged effect on malaria prevalence and 
incidence in a range of transmission settings. We predict that adding ivermectin mass drug 
administration to current interventions can increase impact and help sustain reductions in 
transmission. Due to the operationally synergistic opportunities of co-administering ivermectin with 
other interventions that have the same distribution schedule (mass drug administration with 
antimalarials, and seasonal malaria chemoprevention), and the fact that ivermectin can directly target 
residual transmission that remains even with high coverage of long lasting insecticidal nets and indoor 
residual spraying with insecticides, we believe ivermectin is a powerful new tool which can 
complement existing malaria control efforts.  
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Introduction 
Despite increasing coverage of vector control (long lasting insecticidal nets (LLINs) and indoor residual 
spraying (IRS) with insecticides) and improved access to diagnosis and treatment, there were still an 
estimated 435,000 deaths from malaria in 20171. Novel control methods targeting aspects of the 
transmission cycle currently missed by existing interventions may be needed to further reduce malaria 
burden. LLINs have contributed most to reductions in transmission2 but provide imperfect protection 
against human-vector contact, missing outdoor and early-biting mosquitoes. IRS targets only indoor-
feeding and indoor-resting mosquitoes. Furthermore, there is evidence that mosquitoes are changing 
their behaviour to feed at times when people are not protected by these interventions3. Worryingly, 
insecticide resistance to the main chemicals has been reported worldwide4, resulting in reduced 
efficacy in killing mosquitoes.  
IRS and LLINs will likely remain the cornerstones of malaria control but there is an urgent need for 
additional tools to supplement them. Several novel vector control approaches are being trialled5, 
including attractive targeted sugar baits6 and eave tubes7. Mosquitocidal drugs, such as the 
avermectin class of endectocides, are a potentially impactful novel approach to vector control. 
Endectocides work by killing mosquitoes that feed on humans or animals that have recently taken 
them. Ivermectin is the only drug in the class that is available for human use, and studies have shown 
that it is toxic to mosquitoes, delays refeeding8, reduces fecundity9 and locomotor activity10,  and may 
inhibit sporozoite development11. Ivermectin has many attractive qualities as a novel malaria control 
tool. Unlike IRS and LLINs, it targets mosquitoes regardless of feeding location or time. It can be given 
to cattle, so could be dual-administered to both humans and cattle in areas with zoophilic malaria-
transmitting mosquitoes12. Furthermore, it has a novel model of action, reducing the likelihood of 
cross-resistance with existing insecticides9.  
Mass ivermectin administration could be combined in an operationally opportunistic manner with 
current interventions already being carried out on a large scale across malaria endemic regions. Single 
dose mass drug administration (MDA) with ivermectin (and other anti-helminthic drugs) is carried out 
to control neglected tropical diseases (NTDs) across Africa13 - extending the dosing schedule and 
frequency of administration in line with the malaria transmission season could have an impact on 
malaria transmission. Seasonal malaria chemoprevention (SMC), the monthly distribution of 
antimalarial drugs to children 3-59 months old during the peak months of transmission is being 
implemented in 12 countries in the Sahel region of Africa1. Combining SMC with population-wide 
ivermectin distribution could further protect children from being re-infected and reduce malaria 
transmission. Finally, MDA with antimalarials has been trialled in several malaria endemic countries 
to either accelerate toward elimination14, reduce malaria burden15 or contain the spread of 
artemisinin resistant parasites through local elimination16; ivermectin could be combined with this 
intervention to increase and prolong impact.  
The doses of ivermectin typically used for onchocerciasis and lymphatic filariasis control (singe doses 
of 150-200µg/kg) have a short mosquitocidal effect of around 5-6 days17 and limited impact on 
mosquito populations18 and transmission unless distributed frequently19. Recent clinical trials 
investigating the impact of higher doses have produced promising results. Three doses of 300µg/kg 
given over three days has a mosquitocidal effect in humans for 28 days against Anopheles gambiae 
s.s.20 and a single dose of 400µg/kg was effective for at least ten days against Anopheles minimus and 
6-10 days against Anopheles dirus, two of the most important malaria vectors in Southeast Asia21,22. A 
slow-release ivermectin implant has achieved mosquitocidal concentrations for 40 weeks in cattle12, 
and a novel slow-release, gastric-resident, drug delivery technology in development has achieved 
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mosquitocidal concentrations of ivermectin for around 14 days in pigs23. Fluralaner and afoxolaner, 
two drugs from the isoxazolines class of endectocides used in veterinary medicine, have also been 
shown to be toxic to mosquitoes. Preliminary estimates indicate that they could remain at effective 
mosquitocidal concentrations for 50-90 days, but have not yet been tested for safety in humans24 and  
regulatory approval for human use may take up to a decade25. The combination of non-ivermectin 
mosquitocidal drugs administered to cattle alongside ivermectin administered to humans has been 
suggested as an approach to simultaneously target anthropophilic and zoophilic mosquitoes whilst 
preventing the development of resistance to ivermectin via a dual-chemistry approach which is 
recommended in other forms of vector control26.   
The growing body of evidence that higher doses of ivermectin have a prolonged efficacious duration, 
as well as the development of other slow release or long lasting endectocides has led to calls to better 
understand the potential impact of these drugs on malaria transmission17. In this study, we use a 
mathematical model to estimate the impact of ivermectin MDA and to provide guidance on the 
potential scenarios in which they could complement existing malaria interventions to further reduce 
malaria transmission and burden.  
Methods 
We previously developed a malaria transmission model27 to capture the impact of ivermectin28 on 
vector survival. Here we extend the model to: i) incorporate a range of complementary malaria 
interventions, ii) allow a wider range of mosquitocidal drug profiles, iii) track the parity rate of vector 
populations, and iv) allow for correlation between who receives drugs each round in mass 
administration interventions.  
Malaria transmission model 
The deterministic compartmental model incorporates transmission between mosquito and human 
hosts27,29. Individuals begin life susceptible with a level of maternally-acquired immunity which quickly 
wanes. Upon inoculation with an infectious bite they either become infected (with probability 
determined by their level of pre-erythrocytic immunity), whereupon they either develop clinical 
disease or asymptomatic infection (determined by their levels of blood-stage immunity). Individuals 
with clinical disease have a probability of being successfully diagnosed and treated. Treated individuals 
are prophylactically protected for a duration based on the properties of the antimalarial taken. 
Untreated individuals with clinical disease are assumed to have symptomatic infection for an average 
5 days before transitioning to becoming asymptomatically infected. Asymptomatically infected 
individuals remain infected for an average 310 days27, but their probability of being detectable by 
microscopy decreases over the course of the infection to capture the effect of decreasing parasite 
densities. Individuals that are susceptible or have asymptomatic infection can be superinfected which 
follows the same infection process. The acquisition and loss of immunity is dynamically modelled and 
determines the probability of infection, the probability of developing symptoms and the detectability 
and transmissibility of infection. Transmission from mosquitoes to humans is determined by the 
entomological inoculation rate, which is a product of the mosquito biting rate, sporozoite rate, 
functions determining the relative biting rate on different subgroups (capturing heterogeneity in 
exposure) and age and the probability of successful inoculation. Similarly, transmission from humans 
to mosquitoes is determined by the infectivity of the human, which is based on their infection state, 
the mosquito biting rate, the age- and heterogeneity-biting rates and the probability of successful 
infection. We assume a constant and isolated population, with no movement of infected humans or 
mosquitoes in or out of the intervention area. Details of the model are provided in the Appendix, page 
1-11.  
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Intervention models 
We assess the impact of ivermectin MDA by assuming that a proportion of bloodmeals taken by 
mosquitoes contain ivermectin (determined by the coverage of ivermectin in the human population). 
Mosquitoes ingesting ivermectin transition to a new compartment where they experience an elevated 
mortality rate for the rest of their life. The ‘ivermectin-fed’ compartments are tracked for each day 
post ivermectin-administration, each with a unique mortality rate to capture the elevated but waning 
mosquitocidal effect of ivermectin over time as the concentration in human blood decreases. The 
elevated mortality rates are estimated using a pharmacokinetic (PK)-pharmacodynamic (PD) model30 
which has been fitted to human ivermectin plasma concentrations and corresponding mosquito 
mortality data from feeding experiments conducted using Anopheles gambiae sensu stricto20. Delayed 
refeeding, reduced egg laying and reduced sporogonic development are not explicitly modelled as 
these effects are minimal compared to the mosquitocidal effects28. We also incorporate the impact of 
existing malaria interventions – including LLINs, SMC and MDA – using existing intervention models29.  
Model validation 
The model is validated against data from two ivermectin trials: a study across three countries 
consisting of a single round of ivermectin MDA and focusing on entomological data18, and a cluster 
randomised trial (CRT) conducted in Burkina Faso consisting of a single round of ivermectin MDA in 
the control arm and six rounds of ivermectin MDA in the intervention arm and focusing on clinical 
incidence in a cohort of children ≤5 years old19. This model validation is presented in the Appendix, 
pages 12-17.  
Intervention Scenarios 
We explore the potential impact of ivermectin on malaria prevalence and clinical incidence for the 
scenarios shown in Box 1. The scenarios are simulated in three seasonality ‘archetypes’ that 
encapsulate the range of transmission in sub-Saharan Africa31: i) highly seasonal, based on Fatick in 
Senegal, with a transmission season of approximately 4 months, ii) seasonal, based on Bougouriba in 
Burkina Faso, with a season of 7-8 months, and iii) perennial, based on Equateur in Democratic 
Republic of Congo (DRC), with year-round transmission. Unless stated otherwise, all simulations 
have a mean annual all-age slide prevalence of 30%.  
Ivermectin is recommended for all individuals >15kg / ≥90cm, however, for simplicity we assume all 
children <59 months are below this threshold, and all children ≥59 months are above this threshold. 
Coverage of ivermectin is defined using the number of all individuals ≥5 years old as the denominator. 
Ivermectin is also not recommended for pregnant women, which is why we only consider modest 
coverage estimates (maximum of 70%).  
We consider two ivermectin regimens: a single dose of 400µg/kg (1x400) and three consecutive daily 
doses of 300µg/kg per day (3x300). The former is the highest dose currently recommended for 
lymphatic filariasis MDAs, and the latter is the dose that was viewed as most promising in a recent 
clinical trial20.  
For all scenarios the intervention is introduced optimally in relation to the location-specific seasonality 
profile of each simulation, obtained by simulating the model at different start times and selecting the 
time that results in the greatest reduction in cumulative incidence.  
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Role of Funding Source 
The sponsor of the study had no role in study design, data collection, data analysis, data interpretation, 
or writing of the report. The corresponding author had full access to all the data in the study and had 
final responsibility for the decision to submit for publication. 
 
Results 
The estimated pharmacokinetic profiles of the two dosing regimens are shown in Figure 1a. These 
were combined with the mosquito hazard ratios estimated in Smit et al.20 for each time after 
ivermectin administration that mosquitoes were fed on the treated individuals’ blood (day 2+4hours, 
d7, d10, d14, d21, d28) to estimate the relationship between drug concentration and the mosquito 
hazard ratio (Figure 1b). Figures 1a-b were then combined to estimate the daily hazard of mortality of 
mosquitoes biting each day (Figure 1c).  
 
Ivermectin only MDA 
We first simulated the impact of ivermectin only, assuming all other interventions continued at their 
current coverage levels (Figure 2, Table 1). The impact of ivermectin is predicted to be greatest in the 
setting with the shortest transmission season, with a predicted reduction in clinical incidence of 62% 
and 71% for the 1x400µg/kg and 3x300µg/kg doses respectively. The intervention is predicted to be 
less effective in areas with perennial transmission, where the equivalent reductions are 28% and 31% 
respectively. We predict that ivermectin has a greater impact on incidence than on prevalence. This is 
because the intervention prevents new infections by killing infected and infectious mosquitoes rather 
than clearing older asymptomatic infections.  The sensitivity of these results to the impact of repeat 
ivermectin distribution assuming different durations and magnitudes of mosquitocidal effect 
(including a hypothetical mosquitocidal drug with a 90-day efficacious period), population coverage 
levels, number of rounds and timing between rounds and transmission intensities, and exploring the 
impact of importation of infected individuals into the intervention area, as well as synergies between 
interventions is shown in the Appendix, pages 18-28.   
 
Ivermectin MDA with SMC 
Figure 3 and Table 1 show the estimated impact of population-wide ivermectin MDA in combination 
with SMC Adding ivermectin MDA is predicted to increase the reduction in clinical cases in children <5 
years old compared to SMC alongside existing core interventions. In a highly seasonal setting, we 
predict that SMC alone reduces clinical cases by 58% but adding population-wide ivermectin MDA 
increases this figure to 87% (1x400µg/kg) or 90% (3x300µg/kg) in the year after the start of the 
intervention. This corresponds to an incremental impact on top of SMC alone of 69% and 77%, 
respectively. The reduction in clinical incidence is predicted to be lower in a setting with a longer 
transmission season. Here, the incremental impact of ivermectin is 51% (1x400µg/kg) and 58% 
(3x300µg/kg). The impact of expanding SMC distribution to all individuals under the age of 10 
(alongside ivermectin to individuals over the age of 10) is shown in the Appendix, pages 25-26.  
Delivering SMC to children <5 years old and ivermectin MDA population-wide (≥5 years old) is also 
predicted to have a dramatic impact on population level prevalence – whereas SMC alone is predicted 
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to reduce all-age prevalence by only 19-21%, adding ivermectin (1x400 µg/kg dose) is predicted to 
reduce all-age prevalence by 52% (highly seasonal setting) or 45% (seasonal setting).  
Ivermectin and DHA-P MDA for burden reduction 
The impact of MDA with DHA-P and ivermectin for burden reduction in a highly seasonal moderate 
transmission setting with three rounds spaced one month apart is shown in Fig. 4a,d, and in a 
perennial moderate transmission setting with three rounds spaced one month apart in Fig. 4b,e or 
three rounds spaced four months apart in Fig. 4 c,f. MDA with DHA-P and ivermectin is predicted to 
be most effective in a seasonal transmission setting; predicted reduction in clinical incidence is 91% 
(DHA-P + 1x400µg/kg ivermectin) and 94% (DHA-P + 3x300µg/kg ivermectin) compared to 74% with 
DHA-P alone (Table 1). In a perennial setting, a greater reduction in burden in achieved by spacing the 
rounds evenly throughout the year – in this scenario, the incremental impact of ivermectin in addition 
to DHA-P is also greater (Table 1).  
Ivermectin and DHA-P MDA for elimination 
Figure 5 shows the impact of MDA with DHA-P and ivermectin in a seasonal low transmission setting. 
Here adding ivermectin to DHA-P prevents the rebounds in transmission between rounds and is 
predicted to prolong the overall impact of the MDA intervention.  
Discussion 
Our modelling results predict that ivermectin alone, and to greater extent when combined with 
antimalarial drugs, could have a major and prolonged effect on malaria prevalence and incidence 
across a range of transmission settings. We predict that adding ivermectin MDA to current 
interventions can increase impact and sustain reductions in transmission. Due to the operationally 
synergistic opportunities of co-administering ivermectin with other interventions that have the same 
distribution schedule (MDA with antimalarials, SMC), and the fact that ivermectin can directly target 
residual transmission that remains even with high coverage of vector control, ivermectin may be a 
promising new complementary malaria tool.  
In a seasonal setting, adding ivermectin MDA to SMC has a greater incremental impact on reducing 
prevalence and incidence compared to adding ivermectin MDA to DHA-P MDA, however the total 
impact of the latter intervention is greater. During SMC, a large proportion of the population remain 
untreated and unprotected, therefore adding an intervention that reduces the infectious vector 
population means that these individuals will also receive a benefit. However, MDA with DHA-P 
provides prophylaxis to a larger proportion of the population, so reducing the infectious vector 
population with ivermectin has a lower additional impact as a large proportion cannot be re-infected 
anyway. 
SMC is widely conducted, extremely effective, and a key intervention in in the Sahel region which 
experiences some of the highest rates of malaria worldwide. We predict that administering ivermectin 
to the population ≥5 years old could not only increase the impact of SMC in children under 5, but could 
also increase the population-level benefit, reducing clinical incidence across the whole population.  
Our results suggest that the 3x300µg/kg dose is only marginally more impactful than the 1x400µg/kg 
dose. Although the hazard-ratio area under the curve (and above 1) is 78% greater for 3x300 µg/kg 
compared to 1x400µg/kg (Figure 1c), the highly non-linear effect of increased mortality on the 
proportion of mosquitoes completing sporogony and becoming infectious means that the duration 
the hazard ratio is above some threshold is more important that the magnitude of the hazard ratio. 
Even for a hazard ratio of 2, the proportion of mosquitoes surviving long enough to complete 
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sporogony is 63% lower than in the absence of ivermectin. The hazard ratio is >2 for 14 days with 
3x300 µg/kg and for 10 days with 1x400 µg/kg. The difference between the two regimens is greater in 
a highly-seasonal compared to a perennial setting (Figure 2) because, with the former, ivermectin’s 
effective window covering a greater proportion of annual transmission.  
A key assumption in the ivermectin component of the model is that the hazard ratios observed in a 
clinical laboratory setting can be applied to the known mortality rates of wild mosquitoes. For 
example, we assume that a mosquito dying twice as quickly in the laboratory after a certain dose of 
ivermectin would also die twice as quickly in the wild, albeit with a considerably higher baseline 
mortality rate. In the model, we assume that the mean baseline lifespan of an Anopheles gambiae 
mosquito is 10 days in the wild whereas the lifespan of mosquitoes in laboratory experiments is 
around 14-30 days20,32.  
The model accurately captures changes in entomological outcomes observed in the field; however, 
these field data are limited (Appendix, page 14). Future entomology data collected in  CRTs is therefore 
needed to validate or refine this assumption. The results presented here assume all mosquitoes are 
Anopheles gambiae s.s., however, there is no evidence that other African vectors would be less 
sensitive12,32,33.  
Further limitations include that the 3x300µg/kg hazard estimates were derived directly from data13 
whereas the 1x400µg/kg hazard ratios were estimated using a PK-PD model. The data used to derive 
both sets of hazard ratios were from a trial where ivermectin was co-administered with DHA-P. 
Preliminary data suggest an interaction between these drugs that increases ivermectin bioavailability, 
peak concentration, and mosquito killing effect compared to that of ivermectin alone21. Additionally, 
it remains to be determined whether the observed effect of ivermectin solely reflects that of the 
parent compound, or whether there is also an active ivermectin metabolite with mosquitocidal 
properties21.  
The results presented here assume a constant and isolated population, with no movement of infected 
humans or vectors into or out of the intervention area. Although in a sensitivity analysis (see Appendix, 
pages 24-25) we did not find a major impact of this assumption, further exploration of the effect of 
this intervention in models that capture spatial linkage between populations is warranted.  
To provide empirical evidence for the utility of ivermectin across different settings CRTs are needed. 
An earlier small CRT of repeated ivermectin MDA in Burkina Faso19 found a 19.6% reduction in 
episodes of clinical incidence in a cohort of children ≤5 years old (Appendix, pages 15-17). Whilst the 
1x400µg/kg dose has been used for lymphatic filariasis control, the 3x300µg/kg dose has never been 
delivered at scale to whole populations. An ongoing CRT in The Gambia (NCT03576313) will provide 
evidence on the safety and acceptability of this higher dose (3x300 µg/kg) when given in combination 
with DHA-P. Questions remain surrounding the feasibility of delivering this intervention at scale and 
the implications and potential adherence issues of treating populations with a drug that may provide 
them no direct benefits (if they do not have any other infections that ivermectin treats).  
The appetite from national malaria control programs and funders to implement ivermectin MDA still 
needs to be ascertained. These decisions will depend in part on estimates of cost-effectiveness in 
comparison to other malaria interventions, particularly other novel vector control tools that might be 
targeted in areas with high transmission and high coverage of existing vector control tools. Mass 
ivermectin distribution in Loaisis-endemic regions may require a test-and-not-treat strategy, as it can 
cause adverse events in Loa loa infected individuals34.  
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New longer lasting ivermectin formulations12,23 or other mosquitocidal drugs24 offer a promising new 
opportunity for malaria control, however, the benefit of current formulations of ivermectin should 
not be underplayed. Ivermectin is known to be safe and accepted by communities who have received 
MDAs for decades as part of the control of lymphatic filariasis and onchocerciasis. Ongoing CRTs using 
ivermectin will provide an opportunity to evaluate the impact of mosquitocidal drugs and provide 
evidence to guide decision making for both current and new longer lasting versions of these drugs.  
As of September 2019, in addition to the ivermectin CRT underway in The Gambia, there are four more 
trials (that we are aware of) planned to start in 2019 or 2020. These trials are being conducted in 
different transmission settings with different doses and distribution schedules, different malaria 
vectors, and different coverages of other interventions. Models that have been validated against 
clinical and entomological data, such as the one presented here, will offer a useful way to compare 
results from these diverse trials, to synthesise evidence, and provide a robust framework to 
extrapolate from these trials to wider-scale predictions.   
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Box 1: Details of intervention scenarios 
Complementary 
intervention 
Ivermectin 
interventions  
Intervention 
Frequency 
Example transmission 
setting 
Continue standard 
interventions already 
in place (LLINs, access 
to diagnosis and 
treatment) 
• None 
• Ivermectin-
1x400 MDA 
• Ivermectin-
3x300 MDA 
3 rounds 
one month 
apart  
Highly seasonal (based on 
Fatick, Senegal), moderate 
transmission 
Seasonal (based on 
Bougouriba, Burkina Faso), 
moderate transmission 
Perennial (based on 
Equateur, DRC), moderate 
transmission 
SMC (with sulfadoxine-
pyrimethamine and 
amodiaquine (SP-AQ)) 
to children 3-59 
months old and 
continue standard 
interventions 
• None 
• Ivermectin-
1x400 MDA  
• Ivermectin-
3x300 MDA 
4 rounds 
one month 
apart 
Highly seasonal (based on 
Fatick, Senegal), moderate 
transmission 
Seasonal (based on 
Bougouriba, Burkina Faso), 
moderate transmission 
MDA (with 
dihydroartemisinin-
piperaquine (DHA-P)) 
to all eligible 
population and 
continue standard 
interventions 
• None 
• Ivermectin-
1x400 MDA  
• Ivermectin-
3x300 MDA 
 
3 rounds 
one month 
apart 
Highly seasonal (based on 
Fatick, Senegal), moderate 
transmission  
Perennial (based on 
Equateur, DRC), moderate 
transmission 
Highly seasonal (based on 
Fatick, Senegal), low 
transmission 
3 rounds 
four months 
apart 
Perennial (based on 
Equateur, DRC), moderate 
transmission 
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Ivermectin only 
 
Percentage reduction in clinical 
incidence in all population over 1 
year after start of intervention 
Percentage reduction in mean 
slide prevalence in all population 
over 1 year after start of 
intervention 
Ivermectin dose  
 
1x400µg/kg 3x300µg/kg 1x400µg/kg 3x300µg/kg 
Highly seasonal (Fatick, Senegal) 
 
62% 71% 27% 34% 
Seasonal (Bougouriba, BF) 
 
49% 55% 21% 26% 
Perennial (Equateur, DRC) 
 
28% 31% 13% 15% 
SMC and ivermectin MDA 
 
Percentage reduction in clinical 
incidence in children <5 years old 
over 1 year after start of 
intervention (compared to baseline) 
Percentage reduction in clinical 
incidence in children <5 years old 
over 1 year after start of 
intervention (compared to SMC 
only) 
Complementary intervention SMC to children <5 years old only 
Ivermectin dose  None 1x400µg/kg 3x300µg/kg 1x400µg/kg 3x300µg/kg 
Highly seasonal (Fatick, Senegal) 58% 87% 90% 69% 77% 
Seasonal (Bougouriba, BF) 48% 75% 78% 51% 58% 
MDA with DHA-P and ivermectin  
Percentage reduction in clinical 
incidence in all population over 1 
year after start of intervention 
(compared to baseline) 
Percentage reduction in clinical 
incidence in all population over 1 
year after start of intervention 
(compared to MDA only) 
Complementary intervention MDA with DHA-P  
Ivermectin dose  None 1x400µg/kg 3x300µg/kg 1x400µg/kg 3x300µg/kg 
Highly seasonal (Fatick, Senegal) 
3 rounds 1 month apart 
74% 91% 94% 67% 75% 
Perennial (Equateur, DRC) -  3 
rounds 1 month apart 
50% 66% 68% 31% 36% 
Perennial (Equateur, DRC) -  3 
rounds 4 months apart 
57% 79% 81% 51% 57% 
 
Percentage reduction in slide 
prevalence in all population over 1 
year after start of intervention 
(compared to baseline) 
Percentage reduction in slide 
prevalence in all population over 1 
year after start of intervention 
(compared to MDA only) 
Complementary intervention MDA with DHA-P 
Ivermectin dose  None 1x400µg/kg 3x300µg/kg 1x400µg/kg 3x300µg/kg 
Highly seasonal (Fatick, Senegal) 
3 rounds 1 month apart 
60% 82% 86% 55% 64% 
Perennial (Equateur, DRC) -  3 
rounds 1 month apart 
58% 70% 72% 28% 32% 
Perennial (Equateur, DRC) -  3 
rounds 4 months apart 
64% 78% 79% 38% 43% 
Table 1. Predicted reductions in malaria clinical incidence and prevalence for all intervention 
scenarios described in box 1. Ivermectin only: Percentage reductions in clinical incidence (all ages) and annual mean 
slide prevalence (all ages) from simulations shown in Figure 2 (BF = Burkina Faso). SMC and ivermectin MDA: Absolute and 
incremental (in addition to SMC) percentage reduction in clinical incidence (in children <5 years old), in simulations shown 
in Figure 3. MDA with DHA-P and ivermectin: Absolute and incremental (in addition to MDA with DHA-P) percentage 
reduction in clinical incidence and slide prevalence in simulations shown in Figure 4.  Equations for all ‘percentage 
reduction’ equations are in the Appendix, page 10.  
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Figure legends 
Figure 1: (a) Modelled drug concentrations of 3x300µg/kg and 1x400µg/kg doses of ivermectin35 
estimated using a PK-PD model35 fitted to data in Smit et al.20. (b) Data (dark pink points, with 95% 
confidence intervals) and modelled relationship between drug concentrations and Anopheles 
gambiae mosquito mortality (dark pink line) obtained using local polynomial regression, and the dose-
response relationship (light pink line) used in a previous modelling study28. (c) Hazard ratios for 
Anopheles gambiae mosquito mortality of 3x300µg/kg and 1x400µg/kg doses of ivermectin using 
relationships from (a) and (b).  
 
Figure 2: Clinical incidence per 1,000 all-age population (a,b,c) and annual mean slide prevalence 
(c,d,e) after three rounds of ivermectin one month apart in three different transmission settings. The 
vertical pink lines indicate the timing of the ivermectin MDA rounds. Coverage is assumed to be 70% 
of all individuals over the age of 5.  The baseline scenario assumes standard interventions only (LLINs, 
access to diagnosis and treatment). 
 
Figure 3: Clinical incidence per 1,000 children ≤5 years old after four rounds one month apart of 
SMC, SMC + 1x400µg/kg ivermectin or SMC + 3x300µg/kg ivermectin in a highly seasonal (a) and 
seasonal (b) transmission setting with a pre-intervention mean annual slide prevalence of 30%. We 
assume ivermectin coverage of 70% in individuals over the age of five and SMC coverage of 90% 
children aged 3-59 months. The baseline scenario assumes standard interventions only (LLINs, access 
to diagnosis and treatment). 
 
Figure 4: Clinical incidence per 1,000 all-age population (a,b,c) and annual mean slide prevalence 
(d,e,f) after three rounds of MDA with DHA-P, MDA with DHA-P + 1x400µg/kg ivermectin or MDA 
with DHA-P + 3x300µg/kg ivermectin in a highly seasonal moderate (a,d), and perennial moderate 
(b,e and c,f) transmission setting. The rounds are conducted either one month apart (a,d and b,e) or 
four months apart (c,f). Coverage is assumed to be 70% of all individuals over the age of 5.  The 
baseline scenario assumes standard interventions only (LLINs, access to diagnosis and treatment). 
 
Figure 5: Clinical incidence per 1,000 all-age population (a) and annual mean slide prevalence (b) after 
three rounds of MDA with DHA-P, MDA with DHA-P + 1x400µg/kg ivermectin or MDA with DHA-P + 
3x300µg/kg ivermectin in a highly seasonal low transmission setting.  Coverage is assumed to be 70% 
of all individuals over the age of 5.  The baseline scenario assumes standard interventions only (LLINs, 
access to diagnosis and treatment). 
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